Discontinued — last reported Q3 '25
Alnylam Pharmaceuticals New Operating Lease ROU decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $9.83M to $0.00. Over 4 years (FY 2021 to FY 2025), New Operating Lease ROU shows an upward trend with a 27.9% CAGR.
An increase signals expansion of physical footprint or infrastructure capacity through leasing rather than capital expenditure.
Captures the non-cash impact of recognizing new right-of-use assets and corresponding lease liabilities under accounting...
Standard disclosure under ASC 842 for companies with significant real estate or equipment lease portfolios.
amzn_rou_asset_operating_lease_noncash| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.98M | $1.98M | $1.98M | $253.25K | $253.25K | $253.25K | $253.25K | $642.50K | $642.50K | $642.50K | $642.50K | $774.00K | $7.02M | $1.94M | $0.00 | $9.83M | -$1.29M | $3.84M | $8.82M | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | -87.2% | +0.0% | +0.0% | +0.0% | +153.7% | +0.0% | +0.0% | +0.0% | +20.5% | +806.8% | -72.4% | -100.0% | — | -113.1% | +398.1% | +129.5% | -100.0% |
| YoY Change | — | — | — | — | -87.2% | -87.2% | -87.2% | +153.7% | +153.7% | +153.7% | +153.7% | +20.5% | +992.5% | +201.8% | -100.0% | >999% | -118.4% | +98.1% | — | -100.0% |